<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The relationship between <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> is well recognized, and such patients usually have a high mortality </plain></SENT>
<SENT sid="1" pm="."><plain>We successfully treated a case of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> following living-related orthotopic liver transplantation (LROLT) for non-A, non-B, non-C <z:hpo ids='HP_0012115'>hepatitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A 2-yr-old boy with <z:hpo ids='HP_0004448'>fulminant hepatic failure</z:hpo> from non-A, non-B, non-C <z:hpo ids='HP_0012115'>hepatitis</z:hpo> received LROLT </plain></SENT>
<SENT sid="3" pm="."><plain>Before transplantation, he had <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> which was probably <z:hpo ids='HP_0012115'>hepatitis</z:hpo> associated, and <z:mp ids='MP_0001799'>viral</z:mp> suppression was suspected after bone marrow (BM) biopsy </plain></SENT>
<SENT sid="4" pm="."><plain>After the transplantation, he developed progressive <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> and a diagnosis of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was made via BM biopsy </plain></SENT>
<SENT sid="5" pm="."><plain>With <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> agents (<z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi>), cytokine therapy (granulocyte-colony stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), recombinant human erythropoietin (rhEPO)) was effectual and the patient recovered from <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>He was discharged from the hospital 57 d after the liver transplantation and remains well 1 yr after LROLT </plain></SENT>
<SENT sid="7" pm="."><plain>Combined cytokine therapy with high doses of G-CSF, M-CSF and rhEPO appeared to be effective in the treatment of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> following liver transplantation for non-A, non-B, non-C <z:hpo ids='HP_0012115'>hepatitis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Since M-CSF activates macrophages, it may have contributed to the graft rejection </plain></SENT>
<SENT sid="9" pm="."><plain>Careful consideration should be given to the use of high-dose M-CSF in liver transplant patients </plain></SENT>
</text></document>